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Background: Influenza, like other respiratory viral infections, can cause acute deterioration of lung function in patients with cystic fibrosis (CF). Previous
studies on a small number of patients reported that most people with CF infected with A (H1N1) influenza experienced a mild course of disease.
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371L. Viviani et al. / Journal of Cystic Fibrosis 10 (2011) 370–376Methods: CF centres accessing the web-site of the European Cystic Fibrosis Society (ECFS) were asked to report clinical data on patients with an
ascertained diagnosis of influenza caused by the A (H1N1) virus. The study was web-based and data were collected through an electronic data
sheet on the ECFS website.
Results: Twenty-five centres from 10 countries caring for 4698 patients with CF reported data on 110 patients (2.3%), median age 13 years (range
1–39 years). The prevalence of infection in each centre ranged from 0% to 9.4%. Only 8.8% of the patients had been vaccinated. The main
symptoms were fever and respiratory exacerbation requiring IV antibiotics in 53% of the patients; 48% of the patients were hospitalised for an
average of 12.9 days (range 2–56) and 31% required oxygen treatment during the time of the infection. Most of the patients recovered and FEV1
1 month after the infection was similar to that before the infection. However, 6 patients were admitted to ICU, 5 with mechanical ventilation.
Three patients with severe respiratory disease died.
Conclusions: A (H1N1) influenza infection caused transient but significant morbidity in most of the patients with CF. However, in a small number
of patients with severe lung disease, A (H1N1) influenza was associated with respiratory deterioration, mechanical ventilation and even death.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: A(H1N1); Cystic fibrosis; influenza1. Introduction
Pandemic 2009 influenza A (H1N1) is a new strain of
influenza virus that was first identified in Mexico in March 2009
[1,2]. TheWorldHealthOrganization's declaration of a pandemic
of the novel A (H1N1) influenza virus raises questions regarding
its potential morbidity and mortality. At first sight, the data seem
to imply that this new virus is relatively mild, with case fatality
ratios around 0.5%, which is similar to the upper range of that
seen for seasonal influenza [3], and relatively low hospitalisation
rates. However, the case:fatality ratio seems to vary substantially
between countries, and deaths have occurred in much younger
people than is the case for seasonal influenza [4]. As of July 2010,
more than 214 countries and territories or communitiesworldwide
have reported laboratory confirmed cases of A (H1N1) influenza,
including over 18,398 deaths [5].The Centers for Disease Control
and Prevention (CDC) estimate that in the period April 2009–
April 2010 ~61million cases occurred in the US, ~274,000 cases
were hospitalised and ~12,470 cases died [6]. The majority of
patients with pandemic A (H1N1) influenza infection developed
mild upper respiratory tract symptoms similar to seasonal
influenza. However, from the beginning of the pandemic, reports
of deaths associated with A (H1N1) influenza infection were
reported [7–9]. A weekly surveillance of severe acute respiratory
illness conducted by the European Centre for Disease Prevention
and Control (ECDC) ascertained a cumulative number of
11,593 cases with 575 deaths in 11 countries, corresponding
to an incidence of fatal cases in the population ranging from 0.17
to 1.05 per 100,000 [10] .
In contrast to seasonal influenza, many of the severe
pandemic A (H1N1) influenza cases and their related mortality
have occurred among children and young adults, and about 40%
of the patients that required hospitalisation or died were
previously healthy [11,12]. A study from Argentina reported
that the hospitalisation rate for 2009 A (H1N1) influenza among
children was twice that for 2008 seasonal influenza in the same
population [4]. In the US, the rate of death was 10 times the rate
associated with seasonal influenza for the same population in
2007 and 5 times the rate reported by the CDC for the US
paediatric population during the relatively severe 2003–2004influenza season (0.2 deaths per 100,000 children) [13].
Mortality was particularly high among infants (7.6 deaths per
100,000 children), which was 10 times the US infant death rate
from seasonal influenza in 2003–2004 [13]. Most deaths were
attributable to refractory hypoxemia.
Influenza, like other respiratory viral infections, can cause
acute deterioration of lung function in patients with cystic
fibrosis (CF) [14]. Although vaccination is recommended,
inadequate coverage has been reported [15,16]. Recent reports
from Australia and the UK on a very small number of patients
with CF infected with A (H1N1) virus reported a mild course of
disease with complete recovery [17,18]. The present study was
initiated when the World Health Organisation and the European
health authorities declared the A (H1N1) pandemic. The aim of
this study was to characterise the impact of A (H1N1) infection
on patients with CF on a large number of patients from different
centres and countries.2. Patients and methods
Since a complete list of CF centres throughout Europe does
not exist, we decided to publish a call describing the aims of
the study on the ECFS web site (http://www.ecfs.eu). This web
site is well established in the CF community and regularly
visited. Through the web site the CF centres were asked to
report patients infected with the A (H1N1) virus. The study
was internet-based: participating centres were asked to register
for the study and received a username and password to log in.
Once registered, investigators had to enter CF-centre identifi-
cation information (name of the centre director, name of
the institution, city and country), provide an e-mail address
for contact, and record the total number of patients followed
in the centre. Data were uploaded through the web site of
the CF Centre in Verona and were hosted in the hospital's
server. Help desk was provided by an operator of the CF Centre
in Verona.
Data were collected anonymously (patients were identified
by codes known to the CF centre only). Diagnosis of A
(H1N1) infection was determined by RT-PCR or by direct
immunofluorescence, and/or by epidemiological criteria
Fig. 1. Number of patients diagnosed with A (H1N1) infection in 2009, by week of
diagnosis.
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(H1N1) infection). Centres were asked to also report zero
cases. The reporting period covered the A (H1N1) pandemic
throughout Europe as described and followed by ECDC.
Patients were recruited from July 2009 (28th week of 2009) to
December 2009 and followed until April 2010.
The information collected included age and gender, geno-
type, pancreatic status, previous vaccination against A (H1N1)
virus, date and method of A (H1N1) diagnosis of infection,
symptoms and signs of flu, therapy of A (H1N1) infection
and complications including intravenous antibiotic therapy,
ICU admission and death. The initiation of intravenous
therapy and decision for ICU admission were based on the
clinical assessment of the treating physician at each centre.
The effect on the clinical course of the patient was assessed
by collecting information on pulmonary function (FEV1),
nutritional status (height and weight) and sputum culture before
and after A (H1N1) infection.
We collected FEV1 as absolute values for volume and used
the equations from Hankinson et al. [19] and Wang et al. [20] to
compute FEV1% predicted values.
3. Statistical analysis
Results were summarised as proportions, and Chi-square test
and Fisher's exact test were used to compare proportions across
categories. The Cochran–Armitage test for trend was used to
test whether the proportion of patients reporting symptoms
increased linearly with age. McNemar test was used to assess
whether there was a change in sputum culture before and after
A (H1N1) infection. Statistical significance was considered at
the level of pb0.05.
4. Results
A total of 25 CF centres from 10 countries participated in the
study, caring altogether for 4698 patients (Table 1). Over the
study period, 110 patients (2.3%; 95% CI: 1.9%; 2.8%) were
diagnosed as infected with the A (H1N1) virus; the percent ofTable 1






No. of patients diagnosed with
A (H1N1) infection (%)
Austria 1 40 1 (2.5%)
Belgium 5 793 27 (3.4%)
France 2 325 7 (2.2%)
Germany 1 150 2 (1.3%)
Israel 2 188 9 (4.8%)
Italy 9 2602 50 (1.9%)
Portugal 1 102 4 (3.9%)
Spain 2 219 6 (2.7%)
UK 1 175 2 (1.1%)
USA 1 104 2 (1.9%)
Total 25 4698 110 (2.3%)infected CF patients in the various centres ranged from 0 to
9.4% of the total number of CF patients at each centre. The time
course of the epidemic in CF patients (Fig. 1) was similar to that
reported by the ECDC for the general population. The first case
was reported on the 28th week and the last one on the 52nd
week of 2009. Patients were diagnosed as having A (H1N1)
by RT-PCR (85.5%) or by direct immunofluorescence (7.3%).
In two cases diagnosis was based on epidemiological criteria
(close contact with a patient with laboratory proven A (H1N1)
influenza). Information on mode of A (H1N1) diagnosis was
missing for 2 patients. Only 8.8% of the 110 patients had been
vaccinated against A (H1N1) and 89 patients (81%) were
treated with oseltamivir.
4.1. Clinical presentation
The median age was 13 years (range 1–39 years), and 32
patients were above age 18. Age distribution by gender is
shown in Fig. 2. Of the 110 patients (55.5% males), 84% were
pancreatic insufficient, 36 patients (35%) were homozygous
for the F508del mutation, 50 (48.5%) were heterozygous and
17 (16.5%) did not carry the F508del mutation on either allele.
For 7 patients genotype was not reported.
Presentation of A (H1N1) infection was characterised by the
presence of fever in 94% of the patients, increased cough in
73%, increased sputum production in 54%, fatigue in 51% of
the patients and sore throat in 34%. Five patients (4.5%) had
haemoptysis. Reporting of increased sputum production
increased with age from 17% in the age group 0–5 years to
69% in the age group ≥18 years (test for trend, pb0.001).
Similarly, reports of fatigue increased with age (test for trend,
p=0.005), from 33.3% of patients aged 0–5 years up to 69% of
patients aged 18 years or older.
4.2. Morbidity and mortality
A (H1N1) infection had a significant impact on the
disease course in patients with CF: 58 patients (53%)
required intravenous antibiotic therapy, 53 patients (48%)
were hospitalised for an average of 12.9 days (median: 12,
range: 2–56) and 34 patients (31%) required oxygen treatment
Fig. 2. Age distribution by gender of CF patients reported as infected with A (H1N1).
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treatment in ICU (range: 1–21 days) and five (4.5%) required
non invasive ventilation for 1–15 days. Three patients, all with
previous severe lung disease, died. One of these patients was
on the waiting list for transplantation before he was infectedFig. 3. FEV1% predicted values and BMI in CF patients with A (H1N1)
infection before and 1, 2 and 3 months after A (H1N1) virus infection.by A (H1N1); the other two had FEV1 values below 30% and
BMI of 16.9 and 19.1 kg/m2.
4.3. Pulmonary function
Information on FEV1 values before A (H1N1) infection was
available for 87 of the 97 patients older than 6 years, and
information on FEV1 values 1 month after A (H1N1) infection
was available for 64 patients. Fig. 3 (panel A) shows the mean
FEV1% predicted before A (H1N1) infection and 1, 2 and
3 months after infection. The mean FEV1% predicted prior to
A (H1N1) infection (69.5% predicted, 95% CI: 63.3; 75.7)
was similar to 1 month after A (H1N1) infection (mean: 66%
predicted, 95% CI: 58.6; 73.2). However, variable responses
were observed among the patients: 3 patients had a decrease of
at least 15 percent points, 5 had an increase of at least 15 percent
points and 56 had a variation which was between 15 percent
points decrease and 15 percent points increase. The level of
FEV1 prior to A (H1N1) infection did not correlate with
the change in FEV1 after A (H1N1) infection. It is important to
note that FEV1 values were not available for the patients that
had severe deterioration, i.e. those that were admitted to ICU or
died, and this could affect the results.
Patients who were hospitalised had prior to infection mean
FEV1% values that were significantly lower than those of
patients not admitted (mean, 95% CI admitted: 60.3, 51.5–69.2;
non-admitted: 78.1, 69.9–86.3). Patients with different BMI
values (below and above 18 kg/m2) showed similar FEV1%
values throughout the whole study period.
4.4. Nutrition
Information on BMI before A (H1N1) infection was
available for 101 patients and for 71 patients also 1 month
after infection. Mean BMI before A (H1N1) infection did not
change 1 month after the infection: 18.4 kg/m2 (95% CI: 17.8;
19.1) and 18.4 kg/m2 (95% CI: 17.6; 19.3), respectively.
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pancreatic status, we found in pancreatic insufficient patients
(n=55) an average decrease in BMI of 0.14 kg/m2 (95% CI:
−0.33; 0.05), p=0.002, compared with pancreatic sufficient
patients. Fig. 3 (panel B) shows the mean BMI before A (H1N1)
and up to 3 months after infection. As mentioned above for
FEV1, we did not have BMI values for the more severe patients;
those that were admitted to ICU or died, and this could affect
the results.
4.5. Bacteriology
There was no significant change in sputum culture growth in
the overall group before and after A (H1N1) infection (p=0.99):
8/74 (10.8%) of patients free of Pseudomonas aeruginosa
before infection were positive after infection, whereas 8/37
(21.6%) of patients positive for P. aeruginosa before infection
were negative after infection.
5. Discussion
This study shows that infection with A (H1N1) caused
considerable morbidity to patients with CF, with two-thirds
of the patients requiring intravenous antibiotic therapy, half
requiring hospitalisation and 30% needing supplemental
oxygen treatment during the time of infection. The worst
impact was on 6 patients, all with severe lung disease prior to
the infection, which required treatment in ICU, five of them
needing ventilation and 3 patients died during the course of the
infection. Thus, in the present patient cohort, the majority of the
patients had short term and transient symptoms with recovery to
pre-infection status within 1 month. However, a few patients, all
with pre-existing severe lung disease, were severely affected;
some of them died after being infected by the A (H1N1) virus.
Recent reports demonstrated that hospitalised adults with
A (H1N1) influenza infection were relatively young, and a
significant number (up to 25%) required treatment in the ICU
[21]. The epidemiology of fatal A (H1N1) cases in the United
Kingdom (UK) demonstrated that, unlike seasonal influenza, fatal
cases were mainly seen in young adults. Among patients that
required ICU admission, most developed acute lung injury or
acute respiratory distress syndrome and required mechanical
ventilator support. Severe hypoxemia developing into ARDS
with multi-organ dysfunction in the absence of bacterial infection
was a common clinical presentation [22]. The mortality in these
cases was high and was primarily due to refractory hypoxia.
Again, it appeared that some individuals were predisposed to
develop severe and even fatal disease as a result of A (H1N1)
infection. Underlying risk factors for severe disease were chronic
neurological disease, immunosuppression and respiratory dis-
eases [23]. Other reported risk factors for severe disease and
fatality were pregnancy and obesity [24,25]. A recent study from
the UK demonstrated that the presence of chronic respiratory
diseases other than asthma or COPD increased by an average
of threefold the risk for critical care requirement or death of
patients affected by A (H1N1) infection [26]. Due to the multi-
centre nature of the study, data on population morbidity duringnon-epidemic years could not be obtained and therefore could
not be compared with current morbidity levels. Although ICU
admissions involving CF patients are infrequent events the rate
of ICU admission in the current study (5.4%) seems high.
Previous studies showed that respiratory viral infections
significantly increased respiratory illness and rates of hospita-
lisation in children with CF [14,27–30]. Viral infections were
shown to be one of the main mediators of the onset of chronic
P. aeruginosa infection in CF [31]. Furthermore, a recent
large epidemiological study demonstrated that the influenza
season was associated with increased rates of CF pulmonary
exacerbations [32].The findings in the current study on
A (H1N1) influenza infection in CF are similar to previous
reports of influenza A [14], showing deterioration in pulmonary
function and BMI in only some of the patients. Interestingly,
we did not find a change in the Pseudomonas status in patients
in the first 3 months after A (H1N1) influenza. It is likely
that some patients are prone to develop severe deterioration,
especially those with severe lung disease and patients with
impaired immune response to viral infections. It was recently
shown that various host innate immune responses to different
influenza virus subtypes, or viral haemagglutinin titres, might
be associated with disease severity [33].
To the best of our knowledge, this report is the first multina-
tional study describing a large group of patients with CF with
laboratory confirmed diagnosis of A (H1N1) influenza infection,
covering 25% of the European CF patient population as recorded
in the ECFS Patient Registry [34]. The overall time course of
the A (H1N1) epidemic in CF patients described here followed
the same pattern as observed in the general population, showing
the highest intensity between week 40, 2009 and week 1, 2010,
peaking at week 46, 2009. After this date, for the following
8 weeks, all reporting countries experienced low intensity with
only sporadic cases [10].
Age distribution peaked in the paediatric age and the number
of adult patients (≥18 years) was lower than expected: only
29.3% versus 46.8% reported by the European registry [34].
This finding was not surprising, since it reflects the trend in the
general population. As in the general population, older patients
seem at least partially to be protected by circulating antibodies
from previous seasonal epidemics [35]. The reported A (H1N1)
infection rate in CF patients was low, 2.2%. However, it is
likely that these numbers underestimate the extent of A (H1N1)
infection among patients with CF. It is possible that only the
more severe cases visited the CF centres, and those that were
mildly symptomatic were treated by community physicians.
Furthermore, it is possible that some of the patients that live far
from the centres preferred to be seen by local physicians; for
those no data could be obtained. Only large epidemiological
studies using serological tests would allow to determine spread
of the A (H1N1) among patients with CF, by identifying also
those without or with minor symptoms.
This study did not evaluate the actual vaccination coverage
among CF patients in Europe. However, the finding that only
8.8% of the infected patients were vaccinated against A (H1N1)
is disturbing. All the participating centres declared to have
actively encouraged their patients to be vaccinated, and most
375L. Viviani et al. / Journal of Cystic Fibrosis 10 (2011) 370–376were successful. However, many centres reported that their
patients had been infected before the vaccine was available.
After introduction of the vaccination program only a few new
cases with A (H1N1) infection were identified. Some of the
participating centres reached high coverage, and others reported
that after all their patients had been vaccinated no new case of
A (H1N1) infection was identified. Earlier studies from the US
and France reported influenza vaccination rates in the CF
patient population of ≥75% [16,36]. This number, regarded as
high, indicates that vaccination among patients with high-risk
conditions such as CF is still suboptimal. The recent A (H1N1)
vaccination coverage in the general population was low, despite
a mass vaccination campaign to mitigate the transmission of the
A (H1N1) 2009 pandemic-influenza [37]. This fact could affect
the vaccination rate among patients with CF. We therefore
speculate that earlier and wider coverage of the vaccine would
have lowered the number of hospitalisations and the need for
aggressive treatment, in agreement with the fact that influenza
vaccination is recommended for all patients with CF.
In the present study, 80% of the patients received antiviral
treatment with oseltamivir. It has been shown that early therapy
with oseltamivir, when started during the first 48 hours of
illness, shortened the duration of viral shedding [38]. In the
current study we do not know if oseltamivir was started within
48 hours and if the severe cases deteriorated despite oseltamivir
therapy. Although we did not intend to compare the adverse
pulmonary effect of A (H1N1) with that of other viruses, this
study demonstrates that a viral epidemic or pandemic such as A
(H1N1) can have a significant impact on patients with CF. It is
therefore essential to take serious measures for prevention and
treatment of the disease. Rigorous implementation of hand
washing and avoiding infection transmission through contact
with infected individuals may decrease morbidity and severe
complications in the CF population. In addition, vaccination of
household members, healthcare workers and CF medical teams
is also recommended to reduce the rate of infection among
patients [39]. No clear data are available on the therapeutic
value of preventive post-exposure use of antiviral drugs.
We are now in a post-peak period, with decreased pandemic
activity. However, since it is uncertain if additional waves
will occur, countries should be prepared for a second wave of
infection. Despite previous reports, including only a small
number of patients, showing that A (H1N1) infection caused
mild disease [17,18], this report demonstrates that viral
infection is associated with increased morbidity, and in certain
patients with mortality. We therefore recommend that patients
with CF, their families and their health care providers be aware
of the risks of infection. Early and extensive introduction of
a vaccination campaign should be considered, and methods
to enhance infection control should be rigorously introduced
in order to prevent infection of CF patients.Acknowledgements
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